180 Life Sciences slides on regulatory responses for hand deformity therapy

Forum Markets,

15/06/2022 12:23

** Shares of biotech co 180 Life Sciences  ATNF.O  down ~35%
at $0.87 premarket; stock among worst performers across
exchanges
    ** Co says Tuesday AMC it has received responses from U.K.
and U.S. regulatory authorities for adalimumab, its drug
candidate for early-stage Dupuytren's disease  urn:newsml:reuters.com:*:nGNX79sVxB
    ** Last year, co said mid-stage study testing adalimumab
achieved main goals "by significantly diminishing the hardness
and size of the Dupuytren's nodules"
    ** UK regulator says it is unlikely mid-stage study would be
considered acceptable to support marketing application, while
FDA recommended another meeting to receive further regulatory
guidance
    ** Dupuytren's disease is a hand deformity that usually
develops over the years, affecting a layer of tissue that lies
under the skin of the palm

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))